NEW YORK, August 12, 2013 /PRNewswire/ --
Today, Analysts' Corner announced new research reports highlighting BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX), Exelixis, Inc. (NASDAQ: EXEL), Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX), Puma Biotechnology, Inc. (NYSE: PBYI), and Halozyme Therapeutics, Inc. (NASDAQ: HALO). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
BioCryst Pharmaceuticals, Inc. Research Report
On August 5, 2013, BioCryst Pharmaceuticals, Inc. (BioCryst) announced that underwriters of the Company's recent public offering of its common stock have fully exercised their option to purchase additional 600,000 shares. The Company expects $20.2 million of total gross proceeds from the offering to BioCryst, which includes proceeds from the exercise of the over-allotment option. BioCryst stated that the offering, including the sale of additional shares will close on August 6, 2013 subject to customary closing conditions and it intends to use net proceeds of the same towards second generation hereditary angioedema compounds and pre commercialization activities related to intravenous peramivir. The Full Research Report on BioCryst Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/f9b1_BCRX]
Exelixis, Inc. Research Report
On August 6, 2013, Exelixis, Inc. (Exelixis) reported Q2 2013 financial results. The Company generated net revenues of $11.9 million, up 51.7% YoY. According to Exelixis, the increase was due to $4 million of net product revenue resulting from the sale of COMETRIQ. Net loss was $62.2 million, or $0.34 per basic share, compared with $36.5 million, or $0.25 per basic share, in Q2 2012. Michael M. Morrissey, Ph.D., President and CEO of Exelixis said, "While continuing to focus on enrollment of the COMET phase 3 pivotal trials as our top priority, we initiated the METEOR phase 3 pivotal trial in metastatic hepatocellular carcinoma (HCC). In addition, the overall survival and post-hoc analyses from the phase 2 NRE metastatic CRPC cohort were presented at the ASCO Annual Meeting and those data continue to support the rationale for the COMET pivotal trials in metastatic CRPC, for which we continue to expect top-line data in 2014." The Full Research Report on Exelixis, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/73be_EXEL]
Idenix Pharmaceuticals, Inc. Research Report
On August 7, 2013, Idenix Pharmaceuticals, Inc. (Idenix) reported Q2 2013 financial results with total revenues of $0.1 million, down 92.2% YoY. Q2 2013 net loss was $28.9 million, or $0.22 per basic share, compared with $25.4 million, or $0.23 per basic share, in Q2 2012. Ron Renaud, President and CEO of Idenix said, "In the second quarter, we saw significant progress of our lead HCV development program, samatasvir, and continue to be on track to report data from the first patient cohort in the fourth quarter of this year. We remain committed to our HCV nucleotide franchise, and we are actively pursuing additional paths forward with the ultimate goal remaining the evaluation of an all-oral internally developed pan-genotypic combination regimen including samatasvir and a nucleotide inhibitor." The Full Research Report on Idenix Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/c979_IDIX]
Puma Biotechnology, Inc. Research Report
On August 6, 2013, Puma Biotechnology, Inc. (Puma Biotechnology) reported Q2 2013 financial results. The Company reported Q2 2013 net loss applicable to common stock of $12.6 million, or $0.44 per share, compared with a net loss of $14.8 million, or $0.74 per share, in Q2 2012. Alan H. Auerbach, CEO and President of Puma Biotechnology said, "During the second quarter of 2013, we achieved an important clinical milestone for PB272 with the initiation of our Phase III trial in patients with HER2-positive metastatic breast cancer who have failed two or more prior treatments. We look forward to aggressively recruiting for this trial during the remainder of this year and first half of next year." The Full Research Report on Puma Biotechnology, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/4d27_PBYI]
Halozyme Therapeutics, Inc. Research Report
On August 7, 2013, Halozyme Therapeutics, Inc. (Halozyme) reported Q2 2013 financial results with total revenues of $14.5 million, up 86.3% YoY. Net loss for Q2 2013 was $22.9 million, or $0.20 per share, compared with $14 million, or $0.13 per share, in Q2 2012. Gregory I. Frost, Ph.D., President and CEO of Halozyme said, "Significant regulatory milestones were achieved with Baxter's HyQvia and Roche's Herceptin last quarter. Working with our partners, we look forward to bringing these life-changing treatments to patients and medical communities across Europe." The Full Research Report on Halozyme Therapeutics, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/ea1b_HALO]
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
|SOURCE Analysts' Corner|
Copyright©2012 PR Newswire.
All rights reserved